Search | Clinical Trials Finder

Conditions: Contraception
Interventions: 150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR); Drug
Lead sponsor: Premier Research; Other
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 15
States / cities: Los Angeles, California • Denver, Colorado • Lexington, Kentucky + 11 more

Conditions: Menopause, Hot Flashes
Interventions: Soy Phytoestrogen, Estradiol, Medroxyprogesterone Acetate (MPA), Soy Placebo, MPA Placebo; Dietary Supplement · Drug
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breakthrough Bleeding
Interventions: DR-1031, Seasonale®, Portia®; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 567 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 50
States / cities: Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 45 more

Conditions: Pregnancy Related, Pregnancy Complications, Pregnancy, High Risk
Interventions: Relugolix + Estradiol + Norethindrone Acetate; Drug
Lead sponsor: Sumitomo Pharma Switzerland GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Marlborough, Massachusetts

Conditions: Vaginosis, Bacterial
Interventions: Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring; Drug
Lead sponsor: Eastern Virginia Medical School; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Rheumatoid Arthritis
Interventions: Tocilizumab, Ortho-Novum® 1/35; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 6
States / cities: Little Rock, Arkansas • Beverly Hills, California • Ormond Beach, Florida + 3 more

Conditions: Contraception
Interventions: Ortho-Cyclen (R), Ortho Evra (R), extended use of Ortho Evra (R); Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breakthrough Bleeding, Breakthrough Spotting
Interventions: remove ring if bleeding or spotting occurs more than 5 days, If bleeding does not remove ring; Other
Lead sponsor: Scott and White Hospital & Clinic; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Healthy Volunteers
Interventions: Microgestin®, Levothyroxine, Glyburide, Digoxin, IW-3718; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Breast Cancer
Interventions: Fulvestrant; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: Female only
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 7
States / cities: Little Rock, Arkansas • Boston, Massachusetts • Winchester, Massachusetts + 4 more

Conditions: Healthy
Interventions: Drospirenone/Ethinyl Estradiol (Gianvi®), YAZ®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Contraceptive Usage, Vaginal Epithelial Disruption
Interventions: Desogen (ethinyl estradiol and desogestrel), NuvaRing (ethinyl estradiol and etonogestrel); Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Estrogen Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions: fulvestrant, tipifarnib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Insulin Sensitivity, Cardiovascular Risk, Perimenopausal Disorder
Interventions: Ortho Cyclen®; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Solid Cancers
Interventions: Vismodegib, Rosiglitazone, Norethindrone/ethinyl estradiol; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 3
States / cities: Stanford, California • Detroit, Michigan • Houston, Texas

Conditions: Uterine Hemorrhage, Contraception
Interventions: Combined Oral Contraceptive Pill, Placebo Sugar Pill; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Breast Cancer
Interventions: Ipatasertib, Fulvestrant, Aromatase Inhibitor, Palbociclib; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Neoplasms, Breast Neoplasms
Interventions: Xentuzumab, Abemaciclib, Letrozole, Anastrozole, Fulvestrant; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 6
States / cities: Santa Monica, California • New Haven, Connecticut • Miami, Florida + 3 more

Conditions: Solid Cancers, Non-Hodgkin's Lymphoma
Interventions: Fulvestrant, GDC-0032, Letrozole, Midazolam; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 674 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 27
States / cities: Scottsdale, Arizona • Tucson, Arizona • Orange, California + 20 more

Conditions: Atrophic Vaginitis Due to Menopause
Interventions: Estradiol Vaginal Tablets 10 mcg, placebo; Drug
Lead sponsor: Amneal Pharmaceuticals, LLC; Industry
Eligibility: 30 Years to 75 Years · Female only
Enrollment: 519 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 25
States / cities: Huntsville, Alabama • Montgomery, Alabama • San Diego, California + 19 more

Conditions: Prostate Cancer
Interventions: fulvestrant; Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Postmenopausal Symptoms
Interventions: Estrogel, Placebo; Drug · Other
Lead sponsor: ASCEND Therapeutics; Industry
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 109
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 78 more

Conditions: Uterine Fibroids (UF)
Interventions: Not listed
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 50 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Arlington, Virginia

Conditions: Metrorrhagia
Interventions: Femring®, DepoProvera ®; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Study of the Safety, Efficacy and Cycle Control of a Contraceptive Vaginal Ring

Research Investigation of Soy and Estrogen

A Study to Evaluate Bleeding Patterns With Three Different Doses of DR-1031 Compared to Seasonale

MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy

Effect of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring on Vaginal Innate and Inflammatory Biomarkers

A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis

Oral Versus Patch Hormonal Contraceptive Effects on Metabolism, Clotting, Inflammatory Factors and Vascular Reactivity

Management of Breakthrough Bleeding During Extended Therapy Use With NuvaRing®

Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers

Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer

Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Fasting Conditions.

Hormonal Contraception and Vaginal Health

Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer

Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women

A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

Does Concomitant Use of Combined Oral Hormonal Steroids Stop Bleeding in Women Using Etonogestrel Implants (Implanon/Nexplanon®)?: A Randomized Controlled Study

AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

Study to Evaluate the Safety and Bioequivalence of Estradiol Vaginal Inserts, 10 mcg and Vagifem® 10 mcg and Compare to Placebo

Fulvestrant in Treating Patients With Recurrent Prostate Cancer

Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy

A Study to Evaluate Changes in Hair in Adult Participants Taking Oral Oriahnn Capsules With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)

Pilot Study of Femring Estrogen Supplementation During Depo-Provera Initiation